GlaxoSmithKline builds immunotherapy pipeline with new collaboration

GlaxoSmithKline builds immunotherapy pipeline with new collaboration

GlaxoSmithKline plc (NYSE: GSK) (GSK) has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany to study M7824, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development for multiple difficult-to-treat cancers. Under the terms of the agreement, GSK will pay Merck KGaA $342.3 million (€300 million) upfront. Merck KGaA is also eligible for up to $3.31 billion (€2.9 billion) in milestone payments. The potential deal value could amount to $4.23 billion (€3.7 billion).  Both companies will jointly conduct development and commercialization with all profits and costs from the collaboration being shared equally on a global basis.... Read More »
GlaxoSmithKline Boosts Its Cancer Drug Pipeline

GlaxoSmithKline Boosts Its Cancer Drug Pipeline

British drug giant GlaxoSmithKline (NYSE: GSK) has entered a new oncology arena with its acquisition of Tesaro Inc. (NASDAQ: TSRO) for approximately $5.1 billion. Tesaro is a commercial-stage biopharmaceutical company whose major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved for use in ovarian cancer. Specifically, it is in use in the United States and Europe as a treatment for adulta patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA gene mutation or biomarker status. More tests are under way to assess its use in “all-comers” patient populations, as a... Read More »